Incyte Advances CALR Antibody 989 to Phase 3, Pipeline Diversification Continues

What happened

Incyte CMO Steven Stein outlined development priorities, with a mid-year Phase 3 trial for mutant CALR antibody 989 as a key pipeline update. This program targets a novel antigen in myeloproliferative neoplasms, aiming to expand beyond ruxolitinib-dependent revenue. However, the company remains heavily reliant on Jakafi ($2.26B in first nine months of 2025) and Opzelura, with the 2028 patent cliff dominating the risk profile. The current ~45x EV/EBITDA multiple already prices in a smooth transition, leaving little room for execution missteps. This news adds pipeline optionality but does not alter the fundamental overhang of declining Jakafi revenue before non-Jakafi assets can fully compensate.

Implication

Investors should look for pullbacks toward the $90 attractive entry before establishing or adding positions. Successful Phase 3 data for CALR 989 and tafasitamab approvals by 2028 would support the diversification narrative, but the path is long and risky; patience is warranted until proof of commercial viability emerges.

Thesis delta

The CALR antibody 989 Phase 3 plan adds a longer-term pipeline pillar but does not change the core thesis that Incyte faces a 2028 patent cliff with limited near-term revenue diversification. The stock's elevated multiple (EV/EBITDA ~45x) still discounts a smooth transition that remains unproven, and the news provides no new evidence that Opzelura growth or tafasitamab adoption will meet those high expectations.